Lowest Price Guaranteed From USD 4,899
Published
July 2020
Pages
134
View Count
954
The “Epidermolysis Bullosa Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Epidermolysis Bullosa.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Epidermolysis Bullosa, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030.
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. CURRENT MARKET LANDSCAPE
4.1. Epidermolysis Bullosa: Marketed and Development Pipeline
4.1.1. Analysis by Type of Molecule
4.1.2. Analysis by Phase of Development
4.1.3. Analysis by Mechanism of Action
4.1.4. Analysis by Route of Administration
4.1.5. Analysis by Dosage Form
4.1.6. Analysis by Target Patient Population
4.2. Epidermolysis Bullosa: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Location of Headquarters
4.2.3. Analysis by Geography
5. COMPANY PROFILES
6. KOL ANALYSIS
7. PARTNERSHIPS AND COLLABORATIONS
8. FUNDING AND INVESTMENT ANALYSIS
9. CLINICAL TRIAL ANALYSIS
10. PUBLICATION ANALYSIS
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Epidermolysis Bullosa: Distribution by Type of Molecule
11.2. Epidermolysis Bullosa: Distribution by Route of Administration
11.3. Epidermolysis Bullosa: Distribution by Dosage Form
11.4. Epidermolysis Bullosa: Distribution by Region
12. EXECUTIVE INSIGHTS
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS